Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

PUMA BIOTECHNOLOGY, INC.

PBYI · Nasdaq · CIK 0001401667 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

18 Form 4 transaction lines observed in the same window
10 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchaseNo qualifying purchase is present in the local Form 4 history.

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
WILSON TROY EDWARDDirector
○▼▼
Cesano AlessandraDirector
○○▼
Stuglik Brian MDirector
○▼
Senderowicz AdrianDirector
○▼
MOYES JAY MDirector
○▼
Dorval AllisonDirector
○▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot.—

Recent Form 4 activity

0Purchases
17Sales
11Other Form 4 lines
19SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING10 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,264,923
Previous report
4,319,663
Avg daily volume
304,289
Days to cover
14.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

No qualifying code P equity purchase is present in the local Form 4 history.

Form 4 evidence

28 transaction lines in the latest 365-day window; 284 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14WILSON TROY EDWARDSale (S)Common Stock5,000USD 9.10USD 45,500SEC filing ↗
2026-09-14Cesano AlessandraSale (S)Common Stock62,150USD 9.12USD 566,808SEC filing ↗
2026-09-14Cesano AlessandraOption exercise / conversion (M)Common Stock50,000USD 2.93USD 146,500SEC filing ↗
Show recent Form 4 evidence (28 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14WILSON TROY EDWARDSale (S)Common Stock5,000USD 9.10USD 45,500SEC filing ↗
2026-09-14Cesano AlessandraSale (S)Common Stock62,150USD 9.12USD 566,808SEC filing ↗
2026-09-14Cesano AlessandraOption exercise / conversion (M)Common Stock50,000USD 2.93USD 146,500SEC filing ↗
2026-07-06NOUGUES MAXIMO FSale (S)Common Stock9,386USD 8.26USD 77,528SEC filing ↗
2026-07-06HUNT DOUGLAS MSale (S)Common Stock8,460USD 8.26USD 69,880SEC filing ↗
2026-07-06AUERBACH ALAN HSale (S)Common Stock44,058USD 8.26USD 363,919SEC filing ↗
2026-06-12WILSON TROY EDWARDSale (S)Common Stock10,800USD 7.20USD 77,760SEC filing ↗
2026-06-12Stuglik Brian MSale (S)Common Stock8,100USD 7.20USD 58,320SEC filing ↗
2026-06-12Senderowicz AdrianSale (S)Common Stock27,000USD 7.20USD 194,400SEC filing ↗
2026-06-12MOYES JAY MSale (S)Common Stock22,000USD 7.22USD 158,840SEC filing ↗
2026-06-12Dorval AllisonSale (S)Common Stock11,610USD 7.20USD 83,592SEC filing ↗
2026-06-11WILSON TROY EDWARDAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-06-11Stuglik Brian MAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-06-11Senderowicz AdrianAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-06-11MOYES JAY MAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-06-11MILLER MICHAEL PATRICKAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-06-11Dorval AllisonAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-06-11Cesano AlessandraAward / grant (A)Common Stock27,000USD 0.00USD 0SEC filing ↗
2026-02-18NOUGUES MAXIMO FAward / grant (A)Common Stock46,739USD 0.00USD 0SEC filing ↗
2026-02-18HUNT DOUGLAS MAward / grant (A)Common Stock49,394USD 0.00USD 0SEC filing ↗
2026-02-18AUERBACH ALAN HAward / grant (A)Common Stock159,778USD 0.00USD 0SEC filing ↗
2026-01-07NOUGUES MAXIMO FSale (S)Common Stock6,405USD 5.88USD 37,661SEC filing ↗
2026-01-07HUNT DOUGLAS MSale (S)Common Stock5,014USD 5.88USD 29,482SEC filing ↗
2026-01-07AUERBACH ALAN HSale (S)Common Stock18,012USD 5.88USD 105,911SEC filing ↗
2026-01-06NOUGUES MAXIMO FSale (S)Common Stock4,540USD 5.84USD 26,514SEC filing ↗
2026-01-06HUNT DOUGLAS MSale (S)Common Stock3,973USD 5.84USD 23,202SEC filing ↗
2026-01-06AUERBACH ALAN HSale (S)Common Stock16,938USD 5.84USD 98,918SEC filing ↗
2025-11-11MILLER MICHAEL PATRICKSale (S)Common Stock20,000USD 4.86USD 97,200SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPBYI
CIK0001401667
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history284 transaction lines from 2020-01-02 to 2026-09-14
0 P purchase lines · 199 S sale lines · 85 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.